Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.63 |
| ▸ | EGLN3 | Q9H6Z9 | 8/20 | 0.63 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17641368 | 1.00 | EGLN1 (0.63) | EGLN1EGLN3EGLN2AKR1B1HTT | |
| SCHEMBL17643483 | 0.85 | EGLN1 (0.47) | EGLN1EGLN3EGLN2AKR1B1HIF1A | |
| SCHEMBL17629547 | 0.82 | KDM4E (0.42) | EGLN1EGLN3EGLN2HTTRECQL | |
| SCHEMBL3771822 | 0.79 | EGLN1 (0.86) | EGLN1EGLN3EGLN2 | |
| SCHEMBL17641302 | 0.79 | EGLN1 (0.47) | EGLN1EGLN3EGLN2HIF1A | |
| SCHEMBL960715 | 0.78 | EGLN1 (0.73) | EGLN1EGLN3EGLN2 | |
| SCHEMBL17629614 | 0.77 | EGLN1 (1.00) | EGLN1EGLN3EGLN2 | |
| SCHEMBL3512508 | 0.77 | EGLN1 (0.61) | EGLN1EGLN3EGLN2AKR1B1 | |
| SCHEMBL17629602 | 0.76 | EGLN1 (0.88) | EGLN1EGLN3EGLN2 | |
| SCHEMBL3512528 | 0.75 | EGLN1 (0.59) | EGLN1EGLN3EGLN2AKR1B1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | claimed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | claimed |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | claimed |
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2016045125-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN3 4/4885EGLN2 3/4885 |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN3 4/4885EGLN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.